Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05724563 · ClinicalTrials.gov registry record · Phase 2
Domvanalimab and Zimberelimab in Advanced Liver Cancers
A Phase 2 study of Hepatocellular Carcinoma and Liver Cancer, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT05724563: Active Phase 2 study of Hepatocellular Carcinoma and Liver Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT05724563 is a Phase 2 study of Hepatocellular Carcinoma and Liver Cancer that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 58 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05724563, a Phase 2 study of Hepatocellular Carcinoma and Liver Cancer, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about advanced liver and bile duct cancers. The main question it aims to answer is: If the combination of Domvanalimab and Zimberelimab are effective in treating advanced hepatobiliary cancers that have failed prior treatment.
Primary Outcome
To determine the best objective response rate assessed by RECIST guidelines (version 1.1) of combination zimberelimab and domvanalimab in patients with advanced hepatobiliary cancers previously exposed to anti-PD-1/L1 antibody treatments.
Conditions Studied
Interventions
- DRUG Zimberelimab
- DRUG Domvanalimab
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
What the registry record for NCT05724563 still lists
NCT05724563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (77% lower).
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.
NCT05724563 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05724563 about?
NCT05724563 is a clinical study titled "Domvanalimab and Zimberelimab in Advanced Liver Cancers". The goal of this clinical trial is to learn about advanced liver and bile duct cancers. The main question it aims to answer is: If the combination of Domvanalimab and Zimberelimab are effective in treating advanced hepatobiliary cancers that have failed prior treatment.
What is the current status of trial NCT05724563?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2023-06-01. Estimated completion is 2027-06-01.
What conditions does trial NCT05724563 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma, Hepatobiliary Cancer.
What interventions are being tested in trial NCT05724563?
The interventions under investigation include: Zimberelimab (DRUG), Domvanalimab (DRUG).
Who is sponsoring clinical trial NCT05724563?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05724563 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05724563's enrollment target sits among peer trials
58 80th of 145 higher than 66 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI